ImmuPharma plc (LON:IMM – Get Free Report) hit a new 52-week low on Tuesday . The company traded as low as GBX 3.02 and last traded at GBX 3.21, with a volume of 3799658 shares. The stock had previously closed at GBX 3.50.
ImmuPharma Trading Down 8.4%
The stock has a market cap of £20.00 million, a price-to-earnings ratio of -8.66 and a beta of 3.01. The company has a 50 day simple moving average of GBX 3.89 and a 200-day simple moving average of GBX 4.53.
ImmuPharma (LON:IMM – Get Free Report) last posted its quarterly earnings data on Tuesday, September 15th. The company reported GBX (0.84) earnings per share for the quarter. ImmuPharma had a negative return on equity of 353.21% and a net margin of 3,519.56%. Equities analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
